- Status:
- Topic prioritisation
- Technology type:
- Medicine
- Decision:
- Not selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
- The NICE-Wide Prioritisation Board met on 22 January 2026 and concluded that an evaluation would not be appropriate for this product. The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers concluded that the clear rationale to not evaluate this product is due to commissioning arrangements already being in place for isavuconazol. Given that NICE has not considered antifungals within the TA programme in the past, the board agreed that there would be no value in evaluating isavuconazol for this indication/population. Please see eligibility criteria within the prioritisation manual for further information.
- ID number:
- 12284
Project Team
- Project lead
- Danielle Lees
Email enquiries
If you have any queries please email topic.selection@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 29 January 2026 | Topic prioritisation |
For further information on how we select topics for development, please see our page about topic prioritisation